BioMarin Pharmaceutical Inc. (BMRN)
Largest Insider Buys in Sector
BMRN Stock Price History Chart
BMRN Stock Performance
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. …
Insider Activity of BioMarin Pharmaceutical Inc.
Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $24.17M worth of BioMarin Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $658,092 and sold $25.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.
List of Insider Buy and Sell Transactions, BioMarin Pharmaceutical Inc.
| 2024-11-12 | Sale | EVP, Chief Technical Officer | 5,278 0.0028% | $66.37 | $350,324 | -4.10% | ||
| 2024-08-13 | Sale | GVP, Chief Accounting Officer | 714 0.0004% | $90.00 | $64,260 | 0.00% | ||
| 2024-05-30 | Sale | EVP, Chief Financial Officer | 5,000 0.0027% | $75.19 | $375,950 | +11.61% | ||
| 2024-05-28 | Sale | EVP, Chief Legal Officer | 40,850 0.0215% | $74.51 | $3.04M | +10.03% | ||
| 2024-05-10 | Sale | director | 20,000 0.0105% | $81.14 | $1.62M | -1.65% | ||
| 2024-05-09 | Sale | director | 20,000 0.0105% | $81.62 | $1.63M | -2.09% | ||
| 2024-05-02 | Sale | EVP, Chief Commercial Officer | 5,000 0.0026% | $82.91 | $414,550 | -3.90% | ||
| 2024-05-02 | Sale | EVP, Chief Legal Officer | 1,850 0.001% | $85.01 | $157,269 | -3.90% | ||
| 2024-04-12 | Sale | director | 20,000 0.0104% | $91.26 | $1.83M | -11.27% | ||
| 2024-04-11 | Sale | director | 20,000 0.0105% | $90.99 | $1.82M | -10.38% | ||
| 2024-04-10 | Sale | GVP, Chief Accounting Officer | 2,286 0.0012% | $90.00 | $205,740 | -8.99% | ||
| 2024-03-28 | Sale | EVP, Chief Legal Officer | 24,602 0.0132% | $88.34 | $2.17M | -5.45% | ||
| 2024-03-06 | Sale | director | 1,000 0.0005% | $86.71 | $86,713 | -3.34% | ||
| 2024-03-05 | Sale | director | 1,000 0.0005% | $85.51 | $85,510 | -2.53% | ||
| 2024-03-05 | Sale | President, Worldwide R&D | 35,341 0.0186% | $85.18 | $3.01M | -2.53% | ||
| 2024-03-05 | Sale | EVP, Chief Commercial Officer | 4,000 0.0021% | $87.07 | $348,280 | -2.53% | ||
| 2024-02-27 | Sale | director | 1,000 0.0005% | $90.35 | $90,350 | -7.28% | ||
| 2024-02-09 | Sale | director | 15,000 0.0078% | $88.28 | $1.32M | -4.72% | ||
| 2024-02-08 | Sale | director | 15,000 0.0079% | $89.77 | $1.35M | -4.33% | ||
| 2024-01-10 | Sale | director | 10,000 0.0054% | $96.38 | $963,800 | -11.15% |
Insider Historical Profitability
| BIENAIME JEAN JACQUES | director | 474994 0.2492% | $63.51 | 26 | 321 | +29.88% |
| Mueller Brian | EVP, Chief Financial Officer | 72159 0.0379% | $63.51 | 2 | 32 | +36.78% |
| Davis George Eric | EVP, Chief Legal Officer | 56157 0.0295% | $63.51 | 4 | 73 | +5.04% |
| MEIER RICHARD A | 104032 0.0546% | $63.51 | 4 | 9 | +42.46% | |
| PRICE FREDRIC D | Chief Executive Officer | 79285 0.0416% | $63.51 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| PRIMECAP Management Co | $1.63B | 9.86 | 18.71M | +1.63% | +$26.16M | 1.2 | |
| The Vanguard Group | $1.58B | 9.54 | 18.12M | +0.37% | +$5.86M | 0.03 | |
| BlackRock | $1.26B | 7.63 | 14.48M | -1.38% | -$17.72M | 0.03 | |
| Dodge & Cox | $1.22B | 7.37 | 13.99M | <0.01% | -$97,820.80 | 0.71 | |
| State Street | $602.23M | 3.63 | 6.9M | +2.45% | +$14.38M | 0.03 |